Currently. the search for promising NK1R-positive tumor-targeting radiopharmaceuticals based on the structure of small molecular antagonists of neurokinin-1 receptor can be observed. Following this trend. we continued our evaluation of aprepitant-based 177Lu-radioconjugates in terms of future oncological applications. https://www.marcelovicente.com/product-category/super-skinny-serum/